Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2023

19-11-2023 | Ependymoma | Research

Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT

Authors: Mackenzie Price, Corey Neff, Carol Kruchko, Jill S. Barnholtz-Sloan, Brittany B. Cordeiro, Marta Penas-Prado, Byram H. Ozer, Patrick J. Cimino, Mark R. Gilbert, Terri S. Armstrong, Quinn T. Ostrom

Published in: Journal of Neuro-Oncology | Issue 2/2023

Login to get access

Abstract

Purpose

Incidence, prevalence, and survival are population-based statistics describing cancer burden. The National Cancer Institute’s (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) specializes in tumor biology and outcomes for 12 rare CNS tumor types selected for their importance in adults, research interest, or potential for targeted treatment. The aim of this study was to update incidence, prevalence, and survival statistics for these tumors.

Methods

The Central Brain Tumor Registry of the United States (CBTRUS) database, a combined dataset of Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries (NPCR) and NCI’s Surveillance, Epidemiology and End Results (SEER) data, was used to calculate average annual age-adjusted incidence rates (AAAIR) per 100,000 population overall and by sex, race-ethnicity, and age for diagnosis years 2008–2019. Incidence time trends were calculated for diagnosis years 2004–2019. NPCR data were used to calculate relative survival rates. Point prevalence on December 31, 2019 was estimated using annual age-specific incidence and survival.

Results

AAAIR was 1.47 per 100,000 for these tumors combined, with highest incidence in ependymomas (AAAIR = 0.41/100,000). Most tumor types were more common in males, adults (ages 40 + years) or children (ages < 15 years), and non-Hispanic White individuals. Ependymomas were the most prevalent tumor type (19,320 cases) followed by oligodendrogliomas (14,900 cases). Ependymomas had the highest five-year survival (90.6%) and primary CNS sarcomas the lowest (7.7%).

Conclusions

These data provide means to measure the impact of clinical care and evaluate new therapies and the evolving histopathology definitions in rare CNS tumor types.
Appendix
Available only for authorised users
Literature
4.
go back to reference Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251CrossRefPubMedPubMedCentral Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251CrossRefPubMedPubMedCentral
5.
go back to reference Central Brain Tumor Registry of the United States SEER*Stat Database (2022) CDC National program of cancer registries and NCI surveillance, epidemiology and end results incidence data, 2021 submission (2000–2019) Central Brain Tumor Registry of the United States SEER*Stat Database (2022) CDC National program of cancer registries and NCI surveillance, epidemiology and end results incidence data, 2021 submission (2000–2019)
10.
go back to reference Fay MP, Tiwari RC, Feuer EJ, Zhaohui Z (2006) Estimating average annual percent change for disease rates without assuming constant change. Biometrics 62:847–854CrossRefPubMed Fay MP, Tiwari RC, Feuer EJ, Zhaohui Z (2006) Estimating average annual percent change for disease rates without assuming constant change. Biometrics 62:847–854CrossRefPubMed
13.
go back to reference Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat database: incidence - SEER research plus data, 17 Registries, Nov 2021 Sub (2000–2019) linked To county attributes total U.S., 1969–2020 counties, National Cancer Institute, DCCPS, Surveillance research program, released April 2022, based on the November 2021 submission Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat database: incidence - SEER research plus data, 17 Registries, Nov 2021 Sub (2000–2019) linked To county attributes total U.S., 1969–2020 counties, National Cancer Institute, DCCPS, Surveillance research program, released April 2022, based on the November 2021 submission
14.
go back to reference U.S. Cancer Statistics Working Group (2022) NPCR Survival analytical database, November 2021 Submission, Diagnosis year 2001–2018 U.S. Cancer Statistics Working Group (2022) NPCR Survival analytical database, November 2021 Submission, Diagnosis year 2001–2018
15.
go back to reference Greenfield JP, Castaneda Heredia A, George E, Kieran MW, Morales La Madrid A (2016) Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France. Pediatr Blood Cancer 63:2072–2077. https://doi.org/10.1002/pbc.26169CrossRefPubMed Greenfield JP, Castaneda Heredia A, George E, Kieran MW, Morales La Madrid A (2016) Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France. Pediatr Blood Cancer 63:2072–2077. https://​doi.​org/​10.​1002/​pbc.​26169CrossRefPubMed
16.
go back to reference Louis DN OH, Wiestler OD, Cavanee WK (ed) (2016) WHO Classification of tumours of the central nervous system. International agency for research on cancer, Lyon, France Louis DN OH, Wiestler OD, Cavanee WK (ed) (2016) WHO Classification of tumours of the central nervous system. International agency for research on cancer, Lyon, France
17.
go back to reference Chan MY, Teo WY, Seow WT, Tan AM (2007) Epidemiology, management and treatment outcome of medulloblastoma in singapore. Ann Acad Med Singapore 36:314–318CrossRefPubMed Chan MY, Teo WY, Seow WT, Tan AM (2007) Epidemiology, management and treatment outcome of medulloblastoma in singapore. Ann Acad Med Singapore 36:314–318CrossRefPubMed
18.
go back to reference Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 143:87–93CrossRefPubMedPubMedCentral Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 143:87–93CrossRefPubMedPubMedCentral
22.
go back to reference Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King A, Howell R, Gibson TM, Krull KR, Robison LL, Oeffinger KC, Fouladi M, Armstrong GT (2019) Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the childhood cancer survivor study. J Clin Oncol 37:731–740CrossRefPubMedPubMedCentral Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King A, Howell R, Gibson TM, Krull KR, Robison LL, Oeffinger KC, Fouladi M, Armstrong GT (2019) Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the childhood cancer survivor study. J Clin Oncol 37:731–740CrossRefPubMedPubMedCentral
Metadata
Title
Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT
Authors
Mackenzie Price
Corey Neff
Carol Kruchko
Jill S. Barnholtz-Sloan
Brittany B. Cordeiro
Marta Penas-Prado
Byram H. Ozer
Patrick J. Cimino
Mark R. Gilbert
Terri S. Armstrong
Quinn T. Ostrom
Publication date
19-11-2023
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2023
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-023-04480-7

Other articles of this Issue 2/2023

Journal of Neuro-Oncology 2/2023 Go to the issue